Inclusion Criteria:  The patients with coronary heart disease, the effect of drug treatment is not good, and the clinical manifestations of left ventricular insufficiency occur, EF<40%; Coronary angiography confirmed that there is a chronic occlusive disease of the coronary artery, which is manifested as severe stenosis of single or multiple coronary vessels (≥75%), or even complete occlusion; After the doctor explained the treatment process and possible toxic and side effects, he was willing to treat and agreed to cooperate in the observation of the efficacy. But patients can withdraw from clinical trials and long-term follow-up observation at any time and unconditionally; The patient has no mental illness and language dysfunction and can fully understand the treatment method.  Exclusion Criteria:  Does not meet the above selection criteria; Unable to sign the informed consent form, unable to comply with the agreed timetable of this study; There are reasons to suspect that the patient was forced to join the trial; Acute left ventricular insufficiency, cardiogenic shock; The patient has any infectious diseases (including bacterial and viral infections); Others who are clinically considered unsuitable for this treatment.